Shenqi Fuzheng injection restores the sensitivity to gefitinib in non-small cell lung cancer by inhibiting the IL-22/STAT3/AKT pathway

• Main Authors: Jiali Wang (Author), Xianhai He (Author), Zhirong Jia (Author), Aiwen Yan (Author), Kang Xiao (Author), Shuo Liu (Author), Mengjun Hou (Author), Yaling Long (Author), Xuansheng Ding (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

AbstractContext Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Gefitinib is a first-line treatment for NSCLC. However, its effectiveness is hindered by the development of drug resistance. At present, Shenqi Fuzheng injection (SFI) is widely accepted as an adjuvant therapy...